You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | 2.2% | n/a |
ROCE | 2.8% |
Latest | Forecast | |
---|---|---|
P/E | 24.2 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 3.0 | n/a |
Price / Book value | 3.4 |
Latest | Forecast | |
---|---|---|
Revenue | 96.5% | 11.5% |
PBT | 0.0% | n/a |
EPS | 0.0% | 44.1% |
DPS | n/a | 0.0% |
Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 204.89 | -141.10 | $-0.16 | -31.5 | 0.0 | n/a | n/a | 0.0% |
2020-12-31 | 227.98 | -189.73 | $-0.18 | -34.9 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 356.13 | -215.74 | $0.00 | -2,840.3 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 426.41 | -410.42 | $-0.43 | -7.4 | 0.0 | n/a | n/a | 0.0% |
2023-12-31 | 838.00 | 58.31 | $0.12 | 30.0 | 0.0 | n/a | n/a | 0.0% |
Hutchmed to receive $10m milestone payment from partner Takeda Sharecast News | 13 Dec |
---|---|
Hutchmed lung cancer therapy gets breakthrough designation in China Sharecast News | 12 Dec |
Hutchmed endometrial cancer treatment gets conditional approval in China Sharecast News | 03 Dec |
Blocklisting Six Monthly Return | 30-Dec-24 08:30 |
---|---|
Total Voting Rights | 29-Nov-24 08:30 |
Appointment of Independent Non-executive Director | 20-Nov-24 09:30 |
Total Voting Rights | 31-Oct-24 08:30 |
Vesting of awards under the LTIP | 21-Oct-24 09:30 |